Table 1.
Predicted glycosylation sites (gls) in HML.2, exogenous beta-retroviruses and HIV-1.
| Viruses | Total gls | SU gls | TM gls | TM Ectodomain (a.a./gls) | TM Ectodomain IG (a.a./gls) |
|---|---|---|---|---|---|
| HERV-K108 (HML.2) | 11 | 7 * | 4 | 168/4 | 42 |
| HERV-K109 (HML.2) | 11 | 7 * | 4 | 168/4 | 42 |
| HERV-K113 (HML.2) | 11 | 7 * | 4 | 170/4 | ~42.5 |
| HERV-K115 (HML.2) | 11 | 7 | 4 | 170/4 | ~42.5 |
| HERV-K108 (HML.2) | 11 | 7 | 4 | 170/4 | ~42.5 |
| JSRV | 9 | 6 | 3 | 171/3 | 57 |
| ENTV | 8 | 5 | 3 | 170/3 | ~56.6 |
| MMTV | 5 | 3 | 2 | 168/2 | 84 |
| MPMV | 11 | 10 | 1 | 167/1 | 167 |
| HIV-1 | 31 | 24 | 7 (-3) ** | 170/4 | ~42.5 |
* Excluding glycosylation site in single peptide and/or “NPT” motives in SU. ** Excluding three gls in endodomain.